YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
On August 11, Bicara Therapeutics (NASDAQ:BCAX) used its second-quarter earnings call to deliver two headlines at once. CEO Claire Mazumdar announced she will step into a Vice Chair and Strategic Adviser role at the start of next year, han…
(RTTNews) - Bicara Therapeutics Inc. (BCAX), a clinical-stage biopharmaceutical company, announced financial results for the second quarter reflecting a wider net loss. In addition, the company announced a few management changes and provid…
Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary - Moby Executive Narrative Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. T…
Key Points Interested in Bicara Therapeutics Inc.? Here are five stocks we like better. FICERA's pivotal FORTIFI-HN01 trial remains on track for substantial enrollment by the end of 2026, with an interim analysis planned for mid-2027. Bica…
BOSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the ap…
Claire Mazumdar, Chief Executive Officer of Bicara Therapeutics Inc. (NASDAQ:BCAX), reported the exercise of 15,000 stock options with immediate sale of the resulting common shares on May 18, 2026, as disclosed in the SEC Form 4 filing. Tr…
Key Points CEO Claire Mazumdar sold 15,000 shares for a transaction value of approximately ~$301,000, based on a weighted average price of around $20.04 per share on May 18, 2026. This represented 3.98% of Mazumdar's direct holdings prior…
Omega Fund Management disclosed a buy of 187,500 shares of Bicara Therapeutics(NASDAQ:BCAX) in a May 15, 2026, SEC filing, with the estimated transaction value at $3.23 million based on quarterly average pricing. What happened According to…
On May 15, 2026, Omega Fund Management disclosed in an SEC filing that it sold 411,968 shares of Alumis(NASDAQ:ALMS), with the estimated transaction value at $10.3 million based on quarterly average pricing. What happened According to its…
David Raben, Chief Medical Officer of Bicara Therapeutics Inc.(NASDAQ:BCAX), reported the sale of 5,500 shares of common stock for a transaction value of approximately $126,000 on April 27, 2026, according to the SEC Form 4 filing. Transac…
Stock futures are modestly higher to start the week, indicating a potential rebound at the open following five consecutive weeks of declines across major indexes. Markets are stabilizing slightly after last week’s sustained selloff, but th…
Key Points CEO Claire Mazumdar sold 8,234 common shares for ~$154,000 between March 4 and March 6, 2026, at a weighted average price around $18.74 per share. The transaction represented 2.37% of Mazumdar’s direct common stock holdings, red…
Claire Mazumdar, Chief Executive Officer of Bicara Therapeutics(NASDAQ:BCAX), reported the exercise of 8,234 stock options and immediate sale of the resulting common shares, as disclosed in the SEC Form 4 filing. Transaction summary Metric…
Bicara Therapeutics logo Key Points Breakthrough Therapy Designation was granted for ficerafusp alfa plus pembrolizumab in first-line metastatic/unresectable HPV‑negative HNSCC, and the program has advanced into the Phase III FORTIFY‑HN01…
Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 Announced development of a less frequent loading and every-three-week maintenance dos…
Key Points 8,234 shares were sold for a transaction value of ~$154,000, with weighted average pricing around $18.74 per share on March 4–6, 2026. This sale reduced Mazumdar's direct Common Stock holdings to 339,392 shares post-transaction.…
Claire Mazumdar, Chief Executive Officer of Bicara Therapeutics Inc.(NASDAQ:BCAX), reported the sale of 8,234 shares of Common Stock for a total of approximately $154,000 through open-market transactions from March 4, 2026 to March 6, 2026…
Bicara gains buy rating as BofA sees SoC potential in cancer drug Ficera Proactive uses images sourced from Shutterstock Bank of America has initiated coverage of Bicara Therapeutics (NASDAQ:BCAX) with a “Buy” rating and a $35 price object…
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the pr…
Phase 1b expansion cohort data evaluating 2000mg of ficerafusp alfa every other week in combination with pembrolizumab in 1L HPV-negative R/M HNSCC patients demonstrate rapid, deep and durable responses with generally well-tolerated safety…
Bicara Therapeutics (BCAX) just picked up a double dose of index recognition, joining both the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index. This shift can quietly reshape demand dynamics for its shares. See o…
Bicara Therapeutics Inc. has recently been added to both the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index, marking its inclusion in two widely followed biotechnology benchmarks. This dual index entry can broad…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study interim analysis Totality of data demons…
Granted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC Data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa weekly in combination with pembrolizu…
The ClearBridge Small Cap Strategy underperformed its Russell 2000 Index benchmark during the third quarter, despite registering gains in 10 of the 11 sectors in which it was invested during the quarter. ClearBridge Small Cap Strategy, in…
BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that t…
[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] Danish biotech Genmab (GMAB [https://seekingalpha.com/symbol/GMAB]) is in advanced discussions to acquire Merus (NASDAQ:MRUS [https://seekingalpha.com/…
BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that m…
Investing.com - H.C. Wainwright reduced its price target on Bicara Therapeutics Inc (NASDAQ:BCAX) to $40.00 from $41.00 on Friday, while maintaining a Buy rating on the stock. The $635 million market cap company has seen its shares decline…
[Wall Street sign in Lower Manhattan, NYC] georgeclerk Piper Sandler launched the coverage of a raft of cancer-focused biotechs with bullish views on Monday while issuing a Neutral recommendation on Summit Therapeutics (NASDAQ:SMMT [https:…
[Wall Street New York stock exchange stock market] alexsl Piper Sandler launched coverage for a few biotech companies in the oncology space, as mentioned below: _CG Oncology (NASDAQ:CGON [https://seekingalpha.com/symbol/CGON]) rated Overwe…
* Bicara Therapeutics press release [https://seekingalpha.com/pr/20197307-bicara-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business] (NASDAQ:BCAX [https://seekingalpha.com/symbol/BCAX]): Q2 net loss of $27.4 m…
Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC Data from additional Phase 1/1b expansion cohorts evaluating alternate dose regimens in HPV-negat…
Merus (NASDAQ:MRUS) is one of the most promising stocks according to Wall Street analysts. The 2025 Annual Meeting of the American Society of Clinical Oncology/ASCO, held in Chicago, the US, from May 30 to June 3, featured presentations on…
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental techn…
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that m…